企业档案
会员类型：旗舰版
已获得阿仪网信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
阿仪网旗舰版会员：9年
工商认证 【已认证】
最后认证时间：
注册号： 【已认证】
法人代表： 【已认证】
参观次数：7947075
手机网站：http://wap.app17.com/c137908/
旗舰版网址：http://www.yajiml.com
公司新闻
文献引用产品：人癌胚抗原（CEA）Elisa试剂盒
点击次数：857发布时间：2026/1/22 9:28:26
文章标题：Efficacy ａnd safety analysis of PD-1 combined with regorafenib in the treatment of advanced hepatocellular carcinoma
作者列表：Lu Dong, Pengbin Wang, Yan Pan, Naiying Sun, Gang Yin
期刊：American Journal of Translational Research
发表时间：2024-6-15
影响因子：1.7
DOI:10.62347/IIHG2242
主要研究成果：Abstract
Objective: To investigate the therapeutic efficacy ａnd safety of programmed death-1 （PD-1） inhibitors combined with regorafenib in the treatment of advanced hepatocellular carcinoma （HCC）. Methods: A retrospective analysis was performed on 82 patients diagnosed with advanced HCC at Lanzhou Petrochemical General Hospital ａnd the Second People’s Hospital of Lanzhou City from October 2021 to October 2022. Patients were divided into two groups: the observation group （42 patients） received combined therapy with regorafenib ａnd a PD-1 inhibitor, while the control group （40 patients） received only regorafenib monotherapy. Treatment efficacy, changes in serum tumor markers pre- ａnd post-treatment, incidence of adverse reactions, progression-free survival （PFS）, 1-year survival rate, ａnd independent prognostic factors were evaluated for both groups. Results: The treatment efficacy in the observation group was significantly better than that in the control group （P<0.05）. Post-treatment levels of VEGF, sIL-2R, ａnd CEA were significantly lower in the observation group compared to the control group （all P<0.05）. The incidence of adverse reactions was similar between the two groups （P>0.05）. However, the observation group demonstrated a significantly higher median PFS ａnd 1-year survival rate than the control group （both P<0.05）. Vascular invasion, degree of differentiation, ａnd treatment regimen were identified as independent prognostic factors affecting outcomes （all P<0.05）. Conclusion: For patients with advanced HCC, integrating PD-1 inhibitors with regorafenib treatment not only enhances clinical efficacy but also maintains safety. This combination therapy significantly improves progression-free survival ａnd 1-year survival rates, supporting its further clinical application.
